Government oversight of genetic engineering in the U.S. is on the verge of shifting its concerns from safety in experimentation to areas such as gene therapy and other uses that affect humans directly. To the relief of industrial observers, this oversight will probably focus on clinical applications rather than the manufacturing of substances. Few similiar signs are apparent elsewhere, but other countries are keeping an eye on U.S. developments. Around the world, the trend toward relaxation of regulation continues.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Powledge, T. Surveillance of Genetic Engineering: Will Restraints continue to Loosen?. Nat Biotechnol 1, 322–328 (1983). https://doi.org/10.1038/nbt0683-322
Issue Date:
DOI: https://doi.org/10.1038/nbt0683-322
This article is cited by
-
Applications
Environmental Management (1986)